vinorelbine D-tartrate
vinorelbine
CAS: 71486-22-1
Molecular Formula: C45H54N4O8
vinorelbine D-tartrate - Names and Identifiers
| Name | vinorelbine |
| Synonyms | CL069 CS-404 71486-22-1 vinorelbine vinorelbine D-tartrate nor-5'-anhydrovinblastine ANX-530, KW-2307, 5'-Noranhydrovinblastine 3',4'-didehydro-4'-deoxy-c'-norvincaleukoblastin AspidosperMidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(2R,6R,8S)-4-ethyl-1,3,6,7,8 methyl (2beta,3beta,4beta,5alpha,19alpha)-4-(acetyloxy)-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate methyl (2beta,3beta,4beta,5alpha,12beta,19alpha)-4-(acetyloxy)-15-[(8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate Methyl (2beta,3beta,4beta,5alpha,12beta,19alpha)-4-acetoxy-15-[(12S)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0~3,11~.0~4,9~]octadeca-3(11),4,6,8,15-pentaen-12-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate |
| CAS | 71486-22-1 |
| InChI | InChI=1/C45H54N4O8/c1-8-27-19-28-22-44(40(51)55-6,36-30(25-48(23-27)24-28)29-13-10-11-14-33(29)46-36)32-20-31-34(21-35(32)54-5)47(4)38-43(31)16-18-49-17-12-15-42(9-2,37(43)49)39(57-26(3)50)45(38,53)41(52)56-7/h10-15,19-21,28,37-39,46,53H,8-9,16-18,22-25H2,1-7H3/t28-,37-,38+,39+,42+,43?,44-,45-/m0/s1 |
vinorelbine D-tartrate - Physico-chemical Properties
| Molecular Formula | C45H54N4O8 |
| Molar Mass | 778.93 |
| Density | 1.36±0.1 g/cm3(Predicted) |
| Specific Rotation(α) | D20 +52.4° (c = 0.3 in CHCl3) |
| pKa | 11.36±0.60(Predicted) |
| Refractive Index | 1.676 |
| Physical and Chemical Properties | [Α] D20 52.4 °(C = 0.3, chloroform). UV absorption maximum (ethanol):215,268,282,293,310nm(ε 3700,11000,9500,7600,4400). Vinordbine Ditartrate: C45H54N4O8? 2C4H6O6. Yellow-white amorphous powder. Soluble in water or ethanol. |
vinorelbine D-tartrate - Risk and Safety
| Toxicity | LD50 in mice (mg/m2): 72 i.v.; 78 orally (Mathé, Reizenstein) |
vinorelbine D-tartrate - Reference Information
| efficacy and action | vinorelbine (Navelbine(R)) is a relatively new type of vincristine drug developed by Pierre Fabre in the mid-2090s. It is a semi-synthetic derivative of vinblastine and a drug derived from compounds contained in a class of Vinca rosea. It is a cell cycle specific preparation that has a blocking effect on cell activity in the middle of mitosis (mitosis). Catharine drugs mainly combine with tubulin monomer (monomers), thus inhibiting the formation of microtubules (microtubules). If there are not enough microtubules, the newly replicated chromosome (chromosomes) cannot be pulled apart and cell division will be blocked. Failure of cell division induces apoptosis. The particularity of this product is that it is highly fat-soluble, so it can have complete depolymerization of microtubules. |
| treatable malignant tumor | breast cancer; testicular cancer; epithelial cell carcinoma of the ovary; non-small cell lung cancer. |
| usage and dosage | administration method is generally 25~30mg/m2, intravenous drip, once a week, 4~6 consecutive times as a course of treatment. Recent data show that 50mg/m2, intravenous drip, once every 2~3 weeks can also be tolerated by most patients. |
| adverse reactions | bone marrow suppression is obvious, resulting in decreased number of platelets, red blood cells and white blood cells and anemia, most of which recover within 7 days. Neurotoxicity is mainly manifested by reduced tendon reflex, constipation or diarrhea, and rare paralytic intestinal obstruction. In addition, there are numbness of hands and feet, shortness of breath, nausea, vomiting and hair loss. |
| precautions | 1. because this drug may cause birth defects, women who are pregnant or preparing for pregnancy should not use this drug. Women who are using this medicine should not breastfeed. 2. Patients who use this drug should not be vaccinated, because the drug can cause leukopenia and the body's immunity, which cannot resist infection. Contact with people who have just taken the polio vaccine should also be avoided. 3. It is irritating to the vein and should avoid leakage outside the blood vessel. After the injection, 100~250ml of normal saline should be given to flush the vein. 4, avoid contamination of the eyeball, so as not to cause corneal ulcer. 5. It is effective to store 24 hours in a sealed glass bottle at room temperature after dilution with normal saline or 5% glucose injection. |
| use | is a semi-synthetic periwinkle alkaloid with broad-spectrum anti-tumor activity and low toxicity. Cytotoxicity occurs by interfering with the aggregation of microtubules during cell mitosis. For non-small cell lung cancer, breast cancer, ovarian cancer, soft tissue and visceral metastasis and lymphoma. used for content determination/identification/pharmacological experiment, etc. Pharmacological effect: The main function is to bind to tubulin, so that cells in the process of mitosis in the formation of microtubules. |
| production method | vinorelbine is obtained from dehydrated vinblastine (Anhydmvinblastine) in one or two steps, and the yield is improved. |
| toxic substance data | information provided by: pubchem.ncbi.nlm.nih.gov (external link) |
Last Update：2024-04-09 15:16:44
Supplier List
Spot supply
Product Name: Vinorelbine Visit Supplier Webpage Request for quotationCAS: 71486-22-1
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: Vinorelbine Visit Supplier Webpage Request for quotationCAS: 71486-22-1
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History